GeneDx Holdings Corp. WGS R2KR3KPHARMA
Company Overview
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
Why Investors Should Care
Revenue has grown at a 16.9% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $427.54M (+40.0% YoY); net profit $-21.02M.
- Trailing 12 Months Year-on-year growth — revenue +11.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 16.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 16.86% |
| 1 Year: | 11.40% |
Stock Price Performance
| 1 Year: | -30.35% |
| 6 Months: | -2.69% |
| 3 Months: | +64.22% |
| 1 Month: | +23.21% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)60.21 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 16.9% over 5 years.
CONS
- Trading 48.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | WGS GeneDx Holdings Corp. R2KR3KPHARMA | 85.74 | -21.28 | $2.56B | 0.00% | -3.15% | -40.80% | 16.86% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 46.66M | 30.10M | 38.61M | 63.96M | 64.20M | 47.02M | 43.18M | 57.80M | 53.94M | 36.17M | 83.23M | 43.14M | 48.71M | 53.30M | 62.42M | 70.51M | 76.87M | - | 87.11M | 102.69M | 116.74M | 120.99M | 102.25M | 114.44M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 28.64M | 31.79M | 32.22M | 36.72M | 34.04M | - |
| Gross Profit | 9.52M | -4.40M | 4.59M | -5.67M | -4.32M | -1.16M | -8.31M | -2.81M | 5.62M | -29.60M | 13.55M | 15.24M | 18.76M | 25.26M | 37.41M | 42.95M | 47.83M | - | 58.48M | 70.90M | 84.53M | 84.27M | 68.21M | 78.24M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 63.03M | 61.94M | 87.78M | 98.50M | 94.39M | - |
| Operating Income | -26.77M | -34.16M | -56.02M | -125.05M | -196.66M | -45.45M | -88.26M | -115.78M | -89.31M | -162.65M | -90.82M | -60.36M | -51.62M | -42.97M | -13.66M | -10.58M | -7.78M | - | -4.55M | 8.96M | -3.25M | -14.23M | -26.18M | -17.45M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 236.00K | 17.57M | 3.22M | -7.35M | -54.89M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 640.00K | 817.00K | - | - | 717.00K | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -6.08M | 10.56M | -7.39M | -18.23M | -62.42M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 447.00K | -246.00K | 247.00K | -564.00K | 897.00K | - |
| Net Income | -26.99M | -32.05M | -56.62M | -125.68M | -191.78M | -46.16M | 32.73M | -40.19M | -76.90M | -85.74M | -77.58M | -60.99M | -46.72M | -42.29M | -20.24M | -29.17M | -8.31M | - | -6.53M | 10.81M | -7.63M | -17.67M | -63.32M | -17.74M |
| Diluted EPS | - | - | -456,573.00 | - | -348.82 | -41.94 | 0.16 | - | -10.38 | -8.38 | -6.72 | -3.04 | -1.84 | -1.64 | -0.78 | -1.10 | -0.31 | - | -0.23 | 0.36 | -0.27 | - | -2.16 | -0.60 |
| R&D Expense | 13.10M | 9.36M | 19.08M | 31.16M | 53.13M | 11.95M | 17.83M | 22.25M | 21.32M | 27.17M | 13.35M | 14.59M | 17.14M | 14.29M | 11.57M | 10.90M | 11.66M | - | 12.58M | 15.08M | 19.83M | - | 19.80M | 19.66M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 196.17M | 179.32M | - | 234.69M | 202.57M | 305.45M | 427.54M |
| Cost of Revenue | - | - | - | 261.44M | 112.56M | 111.05M | 129.37M |
| Gross Profit | 82.78M | 4.03M | - | -26.75M | 90.01M | 194.40M | 298.17M |
| Operating Expenses | - | - | - | 430.76M | 260.20M | 217.61M | 311.25M |
| Operating Income | -30.41M | -241.99M | - | -457.51M | -170.19M | -23.21M | -13.08M |
| EBITDA | - | - | - | -398.20M | -136.46M | -1.26M | 12.15M |
| Interest Expense | - | - | 2.83M | 3.21M | - | - | - |
| Pretax Income | - | - | - | -598.03M | -176.69M | -52.63M | -21.14M |
| Tax Provision | - | - | - | -49.05M | -926.00K | -343.00K | -116.00K |
| Net Income | -29.70M | -241.34M | - | -548.98M | -175.77M | -52.29M | -21.02M |
| Diluted EPS | -264,056.00 | -47,036.00 | - | -53.79 | -7.23 | -1.94 | -0.73 |
| R&D Expense | 34.91M | 72.70M | 105.16M | 86.20M | 58.27M | 45.72M | 72.03M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 251.64M | 219.30M | 175.53M | 603.36M | - | 490.94M | 418.76M | 419.38M | 523.71M |
| Current Assets | - | - | - | - | - | - | - | 212.62M | 182.34M | 197.97M | 268.29M |
| Cash & Equivalents | - | - | 108.13M | 58.65M | 26.50M | 461.28M | - | 123.93M | 99.68M | 85.21M | 105.00M |
| Inventory | - | - | - | - | - | - | - | 13.66M | 8.78M | 10.65M | 13.95M |
| Receivables | - | - | - | - | - | - | - | 42.63M | 32.37M | 37.63M | 74.37M |
| Total Liabilities | - | - | 247.25M | 406.68M | 407.60M | 212.34M | - | 237.24M | 190.74M | 174.13M | 215.53M |
| Current Liabilities | - | - | 73.44M | 68.70M | 72.61M | 71.61M | - | 144.30M | 58.82M | 54.82M | 108.91M |
| Long Term Debt | - | - | 18.97M | 18.50M | 18.03M | 11.00M | - | 6.25M | 52.69M | 51.91M | 48.18M |
| Total Debt | - | - | - | - | - | - | - | 77.13M | 119.27M | 117.38M | 113.17M |
| Total Equity | -55.97M | -88.71M | -330.05M | -521.83M | -566.50M | 391.02M | - | 253.71M | 228.02M | 245.25M | 308.18M |
| Shares Outstanding | - | - | - | - | - | - | - | 11.77M | 25.98M | 28.02M | 29.25M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -18.73M | -93.13M | - | -319.15M | -180.15M | -28.50M | 33.28M |
| Investing Cash Flow | -15.46M | -31.97M | - | -141.33M | -43.73M | -30.13M | -61.52M |
| Financing Cash Flow | 148.01M | 129.06M | - | 197.31M | 186.24M | 44.16M | 48.02M |
| Capital Expenditure | -11.92M | -24.09M | - | -14.32M | -5.71M | -5.49M | -19.02M |
| Free Cash Flow | -30.65M | -117.22M | - | -333.48M | -185.86M | -33.99M | 14.26M |
| Net Change in Cash | - | - | - | -263.17M | -37.63M | -14.47M | 19.79M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | 42.2% | 2.2% | - | -11.4% | 44.4% | 63.6% | 69.7% |
| Operating Margin % | -15.5% | -134.9% | - | -194.9% | -84.0% | -7.6% | -3.1% |
| Net Margin % | -15.1% | -134.6% | - | -233.9% | -86.8% | -17.1% | -4.9% |
| ROE % | 33.5% | 73.1% | - | -216.4% | -77.1% | -21.3% | -6.8% |
| ROCE % | - | -135.8% | - | -132.0% | -47.3% | -6.4% | -3.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Corvex Management LP | 16.04% | 4.78M | $413.08M |
| 2 | Casdin Capital, LLC | 12.43% | 3.71M | $320.06M |
| 3 | Blackrock Inc. | 5.72% | 1.71M | $147.31M |
| 4 | Goldman Sachs Group Inc | 5.60% | 1.67M | $144.13M |
| 5 | ARK Investment Management, LLC | 5.40% | 1.61M | $139.02M |
| 6 | William Blair Investment Management, LLC | 4.70% | 1.40M | $120.93M |
| 7 | Morgan Stanley | 3.31% | 988.30K | $85.32M |
| 8 | Oracle Investment Management Inc | 2.97% | 884.65K | $76.38M |
| 9 | Vanguard Capital Management LLC | 2.95% | 879.00K | $75.89M |
| 10 | Citadel Advisors Llc | 2.90% | 865.46K | $74.72M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for WGS
GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children’s
GAITHERSBURG, Md., August 24, 2026--GeneDx and Seattle Children’s show hospital-wide rapid genome sequencing accelerates accurate diagnosis and expands access to answers for children.
Can GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates?
GeneDx Holdings Corp. (WGS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
GeneDx (WGS) Q2 2026 Earnings Call Transcript
Genomic testing volume surged 32% as profitability returned ahead of schedule.
GeneDx Holdings Corp (WGS) (Q2 2026) Earnings Call Highlights: Record Volume and Early ...
GeneDx returns to profitability ahead of schedule, driven by 32% exome and genome volume growth and expanded commercial coverage.
GeneDx Q2 Earnings Call Highlights
GeneDx (NASDAQ:WGS) reported second-quarter revenue of $114.4 million, above its prior guidance, as exome and genome testing volume reached a quarterly record of more than 30,000 tests. The company also returned to adjusted profitability on…
GeneDx Holdings Corp. (WGS) Slid as Revenue Fell Short of Expectations
Fred Alger Management, an investment management company, released its “Alger Small Cap Focus Fund” second-quarter 2026 investor letter. A copy of the letter can be downloaded here. U.S. equities experienced a strong recovery in Q2 2026, wit…
WGS — Frequently Asked Questions
What is the current share price of GeneDx Holdings Corp. (WGS)?
As of 2026-09-07 16:24 PDT, GeneDx Holdings Corp. (WGS) trades at $85.74 on NasdaqGS. Its 52-week range is $34.51 to $167.52.
What is the market capitalisation of WGS?
GeneDx Holdings Corp. (WGS) has a market capitalisation of $2.56B on NasdaqGS.
What is the P/E ratio of WGS?
WGS trades at a trailing price-to-earnings (P/E) ratio of -21.28. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 9.00.
What is the return on equity (ROE) of WGS?
WGS has a return on equity (ROE) of -40.80%. Its return on capital employed (ROCE) is -3.15%.
Is WGS a good stock to buy?
This page provides a data-driven analysis of GeneDx Holdings Corp. (WGS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.